New myeloma treatment provides all-oral regimen option

Ninlaro (ixazomib) is the first proteasome inhibitor to be administered orally.

Taken once weekly in combination with a regimen of lenalidomide and dexamethasone, Ninlaro is indicated in patients with multiple myeloma who have received at least one prior therapy.

In a randomised, double-blind, placebo-controlled pivotal trial in 722 patients with relapsed and/or refractory multiple myeloma, addition of ixazomib to treatment with lenalidomide and dexamethasone was associated with a 40% increase in progression-free survival.

Median progression-free survival was 20.6 months in patients receiving ixazomib plus lenalidomide/dexamethasone compared with 14.7 months in those given placebo plus lenalidomide/dexamethasone (hazard ratio for disease progression or death in the ixazomib group, 0.74; p=0.01).

The rates of serious adverse events, discontinuation due to adverse events, and death during the study period were similar in the two groups.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases